Fifty-eight patients with Raynaud's phenomenon were randomly allocated in a six week double-blind clinical trial in parallel groups to compare the efficacy of a pure antiplatelet agent, ticlopidine (250 mg b.i.d.) with that of a placebo. There was no significant difference between the two treatments in percent re duction of weekly number of attacks and in subjective improvement assessed by both patient and investigator. It is unlikely that platelets are involved in the mechanisms of Raynaud's crisis.
Zahavi J., Hamilton Wap, O'Reilly Mjg, Leyton J., Cotton LT, Kakkar VV: Plasma exchange and platelet function in Raynaud's phenomenon. Thromb Res19:85-93, 1980.
3.
Panak E., Maffrand JP, Picard-Fraire C., Vallee E., Blanchard J., Roncucci R.: Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications. Haemostasis, 13, suppl 1, 1-54, 1983.
4.
Podesda M., Aubert D., Ferrand JC: Contribution à l'étude pharmacologique de thienopyridines et d'analogues furanniques . Eur J Med Chem, 9:483-486, 1974.
5.
Belch Jjf, Cormie J., Newman P., McLaren M., Barbenel J., Capell H., Leiberman P., Forbes CD, Prentice Crm: Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial. Br J Clin Pharmacol15:1135-1165, 1983.
6.
Rustin Mha, Grimes SM, Kovacs, IB, Cooke ED, Bowcock SA, Sowemimo-Coker SO, Turner P., Kirby Jdt: A double-blind trial of UK-38, 485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome. Eur J Clin Pharmacol27:61-65, 1984.
